All posts by: Michael Zand

About Michael Zand

St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease – News-Medical.net

Continue reading

2017-12-11 NEWS

News-Medical.net

St. Jude gene therapy offers hope for infants with ‘bubble boy’ disease
News-Medical.net
Early evidence suggests that gene therapy developed at St. Jude Children’s Research Hospital will lead to broad protection for infants with the devastating immune disorder X-linked severe combined immunodeficiency disorder. Preliminary results from the

Continue reading

2017-12-11 NEWS

STAT

Bluebird’s gene therapy shows strong results in two blood disorders in small trials
STAT
TLANTA — Bluebird Bio (BLUE 1) only discloses gene therapy data on its inherited blood disorder programs twice each year, so expectations — and risks — run high each time the biotech reveals its cards. On Sunday night at the American Society of
bluebird bio Announces Updated Clinical Results from Ongoing …Digital Journal

all 2 news articles »

Continue reading

2017-12-11 NEWS

Engadget

Gene therapy gives ‘bubble babies’ immune systems
Engadget
Initial results from a new gene therapy technique suggest it could open the doors to a cure for “bubble baby” disease. Lacking the ability to ward off even the most common infections, infants born with the genetic disorder — known as severe combined

and more »

Continue reading

2017-12-11 NEWS

Genetic Literacy Project

Fighting infectious diseases with immunotherapy on ‘cusp of commercialization’
Genetic Literacy Project
Pharmaceutical firms have invested billions of dollars in cancer immunotherapies over the last few years, and the US Food and Drug Administration (FDA) began approving such therapies in recent months. But the investment bonanza has yet to hit antiviral

Continue reading

2017-12-11 NEWS

Medical Xpress

CAR T, immunotherapy bring new hope for multiple myeloma patients
Medical Xpress
Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other …
‘Unheard of’ responses to bluebird CART therapy seen in myeloma studyReuters
#ASH17: The BCMA-targeted CART bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News
CAR T, immunotherapy bring new hope for multiple myeloma patientsEurekAlert (press release)

all 18 news articles »